Literature DB >> 16504954

Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer.

C Kichler-Lakomy1, A C Budinsky, R Wolfram, M Hellan, C Wiltschke, T Brodowicz, H Viernstein, Christoph C Zielinski.   

Abstract

PURPOSE: Monocytes derived from patients with early breast cancer (EBC) have shown functional deficiencies. These functional deficiencies are characterized by changes in phenotype and morphology. We have expanded these investigations to dendritic cells generated from monocytes from patients with early breast cancer. - PATIENTS AND METHODS: Peripheral blood from 36 patients with EBC and from 26 healthy age-matched women was drawn and prepared for ex vivo generation of dendritic cells (DC) by incubation with granulocyte/macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL4). The phenotype of DC was examined by flow-cytometry. T cell - proliferation was induced with tetanus toxoid pulsed autologous dendritic cell. -
RESULTS: Dendritic cells generated from monocytes from EBC-patients showed a significantly lower expression of the phenotype-associated antigens CD1a, CD83, CD80, CD86 and CD54 than the dendritic cells from healthy controls. T cell - proliferation in response to TT-pulsed autologous dendritic cells was significantly decreased when induced with dendritic cells from patients with early breast cancer, when compared to healthy controls. Morphologically, only dendritic cells from healthy women possessed prominent dendrites indicating maturity. -
CONCLUSIONS: These findings indicate that dendritic cells generated from monocytes from patients with early breast cancer express an immature phenotype, exhibit immature morphology and show functional deficits when compared to the cells derived from healthy age-matched controls. Whether these findings offer a potential target for therapeutic interventions remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504954

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  10 in total

1.  A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.

Authors:  Osama E Rahma; Ed Ashtar; Malgorzata Czystowska; Marta E Szajnik; Eva Wieckowski; Sarah Bernstein; Vincent E Herrin; Mortada A Shams; Seth M Steinberg; Maria Merino; William Gooding; Carmen Visus; Albert B Deleo; Judith K Wolf; Jeffrey G Bell; Jay A Berzofsky; Theresa L Whiteside; Samir N Khleif
Journal:  Cancer Immunol Immunother       Date:  2011-09-17       Impact factor: 6.968

Review 2.  Tumor associated regulatory dendritic cells.

Authors:  Yang Ma; Galina V Shurin; Dmitriy W Gutkin; Michael R Shurin
Journal:  Semin Cancer Biol       Date:  2012-03-06       Impact factor: 15.707

3.  CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.

Authors:  Carlos López; Ramón Bosch; Anna Korzynska; Marcial García-Rojo; Gloria Bueno; Joan Francesc García-Fontgivell; Salomé Martínez González; Andrea Gras Navarro; Esther Sauras Colón; Júlia Casanova Ribes; Lukasz Roszkowiak; Daniel Mata; Meritxell Arenas; Junior Gómez; Albert Roso; Marta Berenguer; Silvia Reverté-Villarroya; Montserrat Llobera; Jordi Baucells; Marylène Lejeune
Journal:  Breast Cancer       Date:  2022-02-08       Impact factor: 4.239

4.  Myeloid cells in circulation and tumor microenvironment of breast cancer patients.

Authors:  Salman M Toor; Azharuddin Sajid Syed Khaja; Haytham El Salhat; Issam Faour; Jihad Kanbar; Asif A Quadri; Mohamed Albashir; Eyad Elkord
Journal:  Cancer Immunol Immunother       Date:  2017-03-10       Impact factor: 6.968

5.  Antitumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.

Authors:  Mi Tang; Yu Liu; Qiao-Chu Zhang; Peng Zhang; Jue-Kun Wu; Jia-Ni Wang; Ying Ruan; Yong Huang
Journal:  Oncol Lett       Date:  2018-06-21       Impact factor: 2.967

6.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

7.  Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.

Authors:  Smita A Ghanekar; Sonny Bhatia; Joyce J Ruitenberg; Corazon DeLa Rosa; Mary L Disis; Vernon C Maino; Holden T Maecker; Cory A Waters
Journal:  J Immune Based Ther Vaccines       Date:  2007-05-03

8.  Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer.

Authors:  Sri Ramulu Elluru; Jean-Paul Duong van Huyen; Sandrine Delignat; Michel D Kazatchkine; Alain Friboulet; Srini V Kaveri; Jagadeesh Bayry
Journal:  BMC Cancer       Date:  2008-06-04       Impact factor: 4.430

Review 9.  Dendritic cell defects in the colorectal cancer.

Authors:  Annalisa Legitimo; Rita Consolini; Alessandra Failli; Giulia Orsini; Roberto Spisni
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Dysfunctions in the Mature Dendritic Cells Are Associated with the Presence of Metastases of Colorectal Cancer in the Surrounding Lymph Nodes.

Authors:  Anna Pryczynicz; Dariusz Cepowicz; Konrad Zaręba; Mariusz Gryko; Joanna Hołody-Zaręba; Bogusław Kędra; Andrzej Kemona; Katarzyna Guzińska-Ustymowicz
Journal:  Gastroenterol Res Pract       Date:  2015-12-29       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.